CIViC Evidence Items

219 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline

BClinical — prospective trial or retrospective cohort study

CCase study — single case report or small case series

DPreclinical — in vitro or animal model data

EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

	Predictive	Diagnostic	Prognostic	Functional	Predispos.	Oncogenic
BCR::ABL1	323	11
BRAF	186	4	26	2		1
EGFR	248		12	3		2
EML4::ALK	64
ERBB2	142		2
FLT3	55	2	21
KIT	102	3	7
KRAS	159	4	24			4
PIK3CA	156		16	4
PTEN	53	1	3	1	2	1
TP53	52		40	100	2
VHL	5	2	3		635	15

Predictive:Links a variant to treatment response or resistance

Diagnostic:Supports or refutes a specific disease diagnosis

Prognostic:Informs disease progression or clinical outcome

Functional:Characterises the biological effect of a variant

Predisposing:Germline variant associated with cancer predisposition

Oncogenic:Characterises the variant's role in oncogenesis

Level	Gene	Variant	Type	Direction	Significance	Disease	Drugs	Source
B	BRAF	V600E	Diagnostic	Supports	Positive	Papillary Thyroid Carcinoma		Crescenzi et al., 2014
B	BRAF	V600D	Predictive	Supports	Sensitivity/Response	Melanoma	Dabrafenib	Ponti et al., 2013
B	BRAF	V600E	Predictive	Supports	Sensitivity/Response	Melanoma	Trametinib,Dabrafenib	Menzies et al., 2014
B	BRAF	V600E	Prognostic	Does Not Support	Poor Outcome	Papillary Thyroid Carcinoma		Walczyk et al., 2014
B	BRAF	V600E	Prognostic	Supports	Poor Outcome	Colorectal Cancer		Chen et al., 2014
B	BRAF	V600E	Prognostic	Supports	Poor Outcome	Papillary Thyroid Carcinoma		Xing et al., 2014
B	BRAF	V600E	Predictive	Supports	Sensitivity/Response	Melanoma	Vemurafenib	McArthur et al., 2014
A	BRAF	V600E	Predictive	Supports	Sensitivity/Response	Skin Melanoma	Vemurafenib	Chapman et al., 2011
A	BRAF	V600	Predictive	Supports	Sensitivity/Response	Skin Melanoma	Trametinib,Dabrafenib	Robert et al., 2015
B	BRAF	Non-V600	Prognostic	Supports	Better Outcome	Colorectal Cancer		Jones et al., 2017
A	BRAF	V600	Predictive	Supports	Sensitivity/Response	Melanoma	Vemurafenib,Cobimetinib	Ascierto et al., 2016
B	BRAF	V600E	Predictive	Supports	Sensitivity/Response	Melanoma	Dabrafenib,Trametinib	Long et al., 2017
B	BRAF	V600	Predictive	Supports	Sensitivity/Response	Melanoma	Trametinib,Dabrafenib	Long et al., 2017
B	BRAF	V600	Predictive	Supports	Sensitivity/Response	Melanoma	Trametinib,Dabrafenib	Long et al., 2014
B	BRAF	V600E	Predictive	Supports	Sensitivity/Response	Melanoma	Dabrafenib,Trametinib	Long et al., 2014
A	BRAF	V600	Predictive	Supports	Sensitivity/Response	Melanoma	Encorafenib,Binimetinib	Dummer et al., 2018
B	BRAF	V600E	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Encorafenib,Binimetinib,Cetuximab	Kopetz et al., 2019
A	BRAF	V600E	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Encorafenib,Cetuximab	Kopetz et al., 2019
A	BRAF	V600E OR KIAA1549::BRAF Fusion	Predictive	Supports	Sensitivity/Response	Childhood Low-grade Glioma	Tovorafenib	Kilburn et al., 2024
A	BRAF	V600 OR v::BRAF Fusion	Predictive	Supports	Sensitivity/Response	Childhood Low-grade Glioma	Tovorafenib	Kilburn et al., 2024
B	BRAF	V600	Diagnostic	Supports	Positive	Melanoma		Lee et al., 2011
E	BRAF	V600E AND BRAF Amplification	Predictive	Supports	Resistance	Colorectal Cancer	Selumetinib	Corcoran et al., 2010
C	BRAF	L597R	Predictive	Supports	Sensitivity/Response	Melanoma	Vemurafenib	Bahadoran et al., 2013
B	BRAF	V600E	Predictive	Does Not Support	Resistance	Colorectal Cancer	Cetuximab,Panitumumab	Rowland et al., 2015
D	BRAF	Mutation	Predictive	Supports	Sensitivity/Response	Cancer	Trametinib	Jing et al., 2012
B	BRAF	V600E	Diagnostic	Supports	Positive	Hairy Cell Leukemia		Tiacci et al., 2011
B	BRAF	V600K	Predictive	Supports	Sensitivity/Response	Melanoma	Vemurafenib	McArthur et al., 2014
B	BRAF	V600E	Predictive	Does Not Support	Sensitivity/Response	Colorectal Cancer	Vemurafenib	Kopetz et al., 2015
B	BRAF	V600	Predictive	Supports	Sensitivity/Response	Melanoma	Dabrafenib	Falchook et al., 2012
C	BRAF	V600E	Predictive	Supports	Sensitivity/Response	Papillary Thyroid Carcinoma	Vemurafenib	Ali et al., 2014
B	BRAF	V600E	Predictive	Supports	Sensitivity/Response	Melanoma	Vemurafenib,Cobimetinib	Larkin et al., 2014
B	BRAF	V600	Predictive	Supports	Sensitivity/Response	Melanoma	Cobimetinib,Vemurafenib	Larkin et al., 2014
D	BRAF	L505H	Predictive	Supports	Resistance	Melanoma	Vemurafenib	Wagenaar et al., 2014
B	BRAF	V600E	Predictive	Supports	Sensitivity/Response	Melanoma	Vemurafenib	Flaherty et al., 2010
B	BRAF	V600E	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Vemurafenib,Irinotecan,Cetuximab	Hong et al., 2016
B	BRAF	V600E	Prognostic	Supports	Poor Outcome	Colorectal Cancer		Schell et al., 2016
B	BRAF	V600E	Predictive	Supports	Sensitivity/Response	Melanoma	Trametinib	Flaherty et al., 2012
B	BRAF	V600E	Prognostic	Supports	Poor Outcome	Papillary Thyroid Carcinoma		Elisei et al., 2008
A	BRAF	V600E	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Trametinib,Dabrafenib	Planchard et al., 2016
B	BRAF	V600E	Predictive	Supports	Resistance	Colorectal Cancer	FOLFOX-4 Regimen,Cetuximab	Kaczirek et al., 2015
B	BRAF	V600E	Predictive	Supports	Sensitivity/Response	Melanoma	Vemurafenib	Trunzer et al., 2013
B	BRAF	V600E	Predictive	Supports	Sensitivity/Response	Skin Melanoma	Trametinib,Dabrafenib	Robert et al., 2015
D	BRAF	V600D	Predictive	Supports	Sensitivity/Response	Melanoma	Vemurafenib	Yang et al., 2010
B	BRAF	V600	Predictive	Supports	Sensitivity/Response	Cholangiocarcinoma	Vemurafenib	Hyman et al., 2015
B	BRAF	V600E	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Vemurafenib	Hainsworth et al., 2018
B	BRAF	V600	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Encorafenib,Cetuximab	van Geel et al., 2017
B	BRAF	V600E	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Panitumumab,Trametinib,Dabrafenib	Corcoran et al., 2018
B	BRAF	V600K	Predictive	Supports	Sensitivity/Response	Melanoma	Dabrafenib,Trametinib	Long et al., 2017
B	BRAF	V600E	Predictive	Supports	Sensitivity/Response	Melanoma	Trametinib,Dabrafenib	Flaherty et al., 2012
D	BRAF	V600E AND EZH2 Y646F	Predictive	Supports	Sensitivity/Response	Melanoma	JQEZ5	Souroullas et al., 2016

Page 1 of 5